Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$38.48 USD

38.48
801,093

-0.48 (-1.23%)

Updated Oct 18, 2024 11:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sanofi (SNY) Ends mRNA COVID Vaccine Bid Despite Positive Data

by Zacks Equity Research

Sanofi (SNY) dumps development of mRNA-based COVID vaccine despite promising data from an early study. Instead, it will focus on its adjuvanted recombinant protein vaccine candidate.

How Investors Can Grab Better Returns for Medical Using the Zacks ESP Screener

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Regeneron (REGN) Antibody Cocktail REGEN-COV Gets WHO Recommendation

by Zacks Equity Research

Regeneron (REGN) monoclonal antibody cocktail is being conditionally recommended by WHO for the treatment of certain patients with COVID-19. However, the high cost is a deterrent.

Lilly (LLY) to Supply COVID Cocktail Drug to EU Countries

by Zacks Equity Research

Elli Lilly (LLY) is set to supply 220,000 doses of its COVID-19 antibody cocktail to European Union member nations, following approval.

Glaxo's (GSK) Nucala Gets CHMP Nod for 3 Diseases in Europe

by Zacks Equity Research

Glaxo (GSK) is seeking approval of Nucala for hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis) and chronic rhinosinusitis with nasal polyps in Europe

Lilly (LLY) Gets FDA Nod for Expanded Use of COVID Cocktail

by Zacks Equity Research

FDA revises Lilly's (LLY) EUA for COVID-19 antibody cocktail, bamlanivimab and etesevimab, for post-exposure prophylaxis for COVID-19.

Regeneron, Lilly Get New COVID Drug Deals From Government

by Zacks Equity Research

Regeneron (REGN) is set to supply an additional 1.4 million doses of its antibody cocktail for COVID-19, REGEN-COV while Lilly (LLY) will supply 388,000 doses of its COVID-19 antibody medicine, etesevimab to the U.S. government.

HOOKIPA (HOOK), Merck Collaborate to Treat Head & Neck Cancers

by Zacks Equity Research

HOOKIPA (HOOK) collaborates with Merck (MRK) to evaluate the combination of its immunotherapy program, HB-200, with Merck's Keytruda for advanced head and neck squamous cell carcinoma.

Theravance (TBPH) to Cut Workforce, Hypotension Study Fails

by Zacks Equity Research

Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic neurogenic orthostatic hypotension fails to meet goal. The company plans to cut its workforce by 75%. Stocks falls.

AstraZeneca (AZN) Asthma Candidate Meets Primary Study Goals

by Zacks Equity Research

AstraZeneca's (AZN) phase III studies evaluating its investigational inhaler PT027 for asthma meets primary endpoints.

Adaptimmune (ADAP) Gains on Deal With Roche for Cell Therapies

by Zacks Equity Research

Adaptimmune (ADAP) shares jump on a collaboration and license agreement with Roche for the development of allogeneic T-cell therapies for up to five shared cancer targets.

Merck's (MRK) Keytruda Gets Nod for Expanded Use in China

by Zacks Equity Research

Merck's (MRK) Keytruda gets approval in combination with chemotherapy in the first-line setting for advanced esophageal and GEJ cancer in China based on data from the phase III KEYNOTE-590 study.

Will Regeneron's (REGN) Antibody Cocktail Fuel Further Growth?

by Zacks Equity Research

Regeneron's (REGN) performance in the year has gained from higher demand for its antibody cocktail - REGEN-COV.

Adaptimmune (ADAP) Presents Data on Liver Cancer Candidate

by Zacks Equity Research

Adaptimmune (ADAP) announces encouraging data from an early-stage study on liver cancer patients from its cell therapy candidate.

Pfizer (PFE) Begins Study on RSV Vaccine in Older Adults

by Zacks Equity Research

Pfizer (PFE) starts a phase III study which will evaluate its respiratory syncytial virus vaccine candidate, RSVpreF in adults aged 60 years and above.

GlaxoSmithKline (GSK) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

GlaxoSmithKline (GSK) closed at $41.43 in the latest trading session, marking a +0.78% move from the prior day.

Glaxo (GSK), SK bioscience's COVID-19 Jab Enters Phase III Study

by Zacks Equity Research

GlaxoSmithKline (GSK) and SK bioscience begin a phase III study on GBP510, the latter's COVID-19 vaccine candidate. The study will compare GBP510 against AstraZeneca's COVID-19 vaccine.

J&J's (JNJ) HIV Vaccine Study in Young African Women Fails

by Zacks Equity Research

J&J's (JNJ) mid-stage study shows HIV vaccine fails to provide enough protection against HIV in young women in Africa.

Merck's (MRK) Keytruda Gets Full Approval for Bladder Cancer

by Zacks Equity Research

Merck's (MRK) anti-PD-1 therapy, Keytruda, gets full approval from the FDA as a first-line treatment for bladder cancer, after having enjoyed accelerated approval for the indication.

Kinjel Shah headshot

3 Big Drug/Biotech Outperformers Worth Keeping an Eye On (Revised)

by Kinjel Shah

Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

Theravance (TBPH) Suffers 2nd Study Failure in Two Months

by Zacks Equity Research

Theravance's (TBPH) mid-stage candidate, izencitinib, fails in a study evaluating it in patients with ulcerative colitis.

Regeneron (REGN) COVID-19 Antibody Cocktail Gets CMA in the UK

by Zacks Equity Research

Regeneron (REGN) gets Conditional Marketing Authorization for its antibody cocktail, casirivimab and imdevimab for COVID-19 infection in the United Kingdom.

Gilead (GILD) MAA for HIV Inhibitor Under the EMA's Review

by Zacks Equity Research

Gilead's (GILD) application for an investigational, long-acting HIV-1 capsid inhibitor, lenacapavir, is under review with the European regulatory body.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod for MRK, PFE Products & New Use of LLY, GSK Drugs

by Kinjel Shah

FDA approves Merck's (MRK) Welireg and Pfizer's (PFE) TICOVAC vaccine and new indications for Lilly's (LLY) Jardiance and Glaxo's (GSK) Jemperli.

Sheraz Mian headshot

Top Analyst Reports for Chevron, T-Mobile & American Express

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), T-Mobile US, Inc. (TMUS), and American Express Company (AXP).